Optimization of multigene analysis of tumor samples

Patent metadata

Field	Value
Publication number	US-12180540-B2
Application number	US-202217812415-A
Country	US
Kind code	B2
Filing date	Jul 13, 2022
Priority date	Dec 30, 2010
Publication date	Dec 31, 2024
Grant date	Dec 31, 2024

Abstract

A method of analyzing a tumor sample comprising:
(a) acquiring a library comprising a plurality of tumor members from a tumor sample; (b) contacting the library with a bait set to provide selected members; (c) acquiring a read for a subgenomic interval from a tumor member from said library; (d) aligning said read; and (e) assigning a nucleotide value (e.g., calling a mutation) from said read for the preselected nucleotide position, thereby analyzing said tumor sample.

First claim

What is claimed is:

1. A method of separating targeted nucleic acid molecules from a sample, comprising:
combining, in the same solution, at least two different bait sets and a library comprising a plurality of nucleic acid molecules to form a plurality of nucleic acid hybrids, wherein the at least two different bait sets each comprise one or more bait molecules comprising a binding entity and a sequence configured to capture a target sequence, wherein the nucleic acid hybrids comprise a target nucleic acid molecule and a bait molecule, and wherein the at least two different bait sets comprise:
a first bait set comprising a bait molecule comprising a sequence configured to capture a target sequence comprising a point mutation, and
a second bait set comprising a bait molecule comprising a sequence configured to capture a target sequence comprising a structural breakpoint; and

separating the plurality of nucleic acid hybrids from a remainder of the library.

2. The method of claim 1 , further comprising sequencing target nucleic acid molecules in the plurality of nucleic acid hybrids separated from the remainder of the library.

3. The method of claim 2 , wherein the target sequence comprising the point mutation is sequenced at a first sequencing depth and the target sequence comprising the structural breakpoint is sequenced at a second sequencing depth, and wherein the first sequencing depth differs from the second sequencing depth by at least a 2-fold.

4. The method of claim 2 , wherein the sequencing is next generation sequencing.

5. The method of claim 1 , wherein the plurality of nucleic acid molecules comprises DNA molecules.

6. The method of claim 1 , further comprising amplifying target nucleic acid molecules in the plurality of nucleic acid hybrids.

7. The method of claim 1 , comprising attaching sequencing adapters to the plurality of nucleic acid molecules in the library.

8. The method of claim 7 , wherein the sequencing adapters comprise a barcode sequence.

9. The method of claim 1 , wherein the plurality of nucleic acid molecules comprises cDNA molecules derived from RNA molecules.

10. The method of claim 1 , wherein the structural breakpoint comprises an in-frame deletion of one or more codons, an intragenic deletion, and intragenic insertion, deletion of a full gene, an inversion, an interchromosomal translocation, a tandem duplication, a gene fusion, or a genomic rearrangement that comprises an intron sequence.

11. The method of claim 1 , wherein the structural breakpoint is an exon-exon junction.

12. The method of claim 1 , wherein the binding entity comprises biotin.

13. The method of claim 1 , wherein the point mutation or the structural breakpoint is associated with a cancerous phenotype.

14. The method of claim 13 , wherein the cancerous phenotype comprises a cancer risk, a cancer progression, a clinical outcome or responsiveness to therapy, or a resistance to cancer treatment.

15. The method of claim 1 , wherein the size of the nucleic acid molecules in the plurality of nucleic acid molecules is 600 bp or less.

16. The method of claim 1 , wherein the size of the sequence of the bait molecules is about 100 to about 300 bases.

17. The method of claim 1 , wherein the plurality of nucleic acid hybrids are separated from a remainder of the library using a plurality of beads.

18. The method of claim 17 , wherein the binding entity comprises biotin and the beads in the plurality of beads are coated with streptavidin.

19. The method of claim 1 , wherein the at least two different bait sets and the library are combined in solution.

20. A method of separating targeted nucleic acid molecules from a sample, comprising:
combining, in the same solution, at least two different bait sets and a library comprising a plurality of nucleic acid molecules to form a plurality of nucleic acid hybrids, wherein the at least two different bait sets each comprise one or more bait molecules comprising a binding entity and a sequence configured to capture a target sequence, and wherein the plurality of nucleic acid hybrids comprises:
a first nucleic acid hybrid comprising a bait molecule from the first bait set and a target nucleic acid molecule comprising a point mutation, and
a second nucleic acid hybrid comprising a bait molecule from the second bait set and a target nucleic acid molecule comprising a structural breakpoint; and

separating the plurality of nucleic acid hybrids from a remainder of the library.

Assignees

• Found Medicine Inc

Inventors

• Lipson Doron
• Otto Geoffrey Alan
• Parker Alexander Nevin
• Stephens Philip James
• Downing Sean R
• Jarosz Mirna
• Shapiro Mikhail G
• Yelensky Roman

Classifications

• C12Q2537/149

  Sequential reactions · CPC title

• C12Q2537/143

  Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis · CPC title

• G16B30/00

  ICT specially adapted for sequence analysis involving nucleotides or amino acids · CPC title

• G16B20/00

  ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations · CPC title

• G16B20/20

  Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection · CPC title